{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:35:39Z","timestamp":1791498939162,"version":"4.3.4"},"reference-count":132,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HemaSphere"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Mantle cell lymphoma (MCL) is a relatively rare B\u2010cell lymphoma subtype, with a higher incidence among males and a median age of 70 years at diagnosis. MCL is characterized by clinically diverse behavior, from indolent disease to extremely aggressive, related to the presence of biological risk factors such as proliferation rate and\n                    <jats:italic>TP53<\/jats:italic>\n                    mutations. Most often, patients present with disseminated disease, necessitating systemic treatment. Immunochemotherapy has historically been the mainstay of treatment, but recent data indicate that addition of novel agents, especially covalent Bruton tyrosine kinase inhibitors (cBTKi), may substantially improve outcome in younger and older patients, although a curative approach remains to be shown. In elderly patients, the standard of care is still immuno\u2010chemotherapy such as rituximab\u2010bendamustine, although this may be challenged by non\u2010chemotherapeutic options, such as rituximab plus cBTKi. For patients with relapsed or refractory disease, treatment options are developing rapidly, including CAR\u2010T cell therapy, novel BTK targeting agents, BCL2 inhibitors, and T\u2010cell engagers. In this clinical practice guideline, we present current evidence\u2010based recommendations for diagnosis, staging, treatment, and follow\u2010up of MCL.\n                  <\/jats:p>","DOI":"10.1002\/hem3.70233","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:20:51Z","timestamp":1761128451000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["EHA\u2013EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4509-6707","authenticated-orcid":false,"given":"Mats","family":"Jerkeman","sequence":"first","affiliation":[{"name":"Department of Oncology Sk\u00e5ne University Hospital Lund Sweden"},{"name":"Lund University Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Aurer","sequence":"additional","affiliation":[{"name":"University Hospital Centre Zagreb and Medical School, University of Zagreb  Zagreb Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Campo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital Cl\u00ednic de Barcelona Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), University of Barcelona, CIBERONC Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan Y.","family":"Cheah","sequence":"additional","affiliation":[{"name":"Department of Hematology Sir Charles Gairdner Hospital Perth Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9551-9662","authenticated-orcid":false,"given":"Jonathan","family":"Clark","sequence":"additional","affiliation":[{"name":"Inspire2Live Loosdrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Doorduijn","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus MC Cancer Institute University Medical Center Rotterdam  The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby A.","family":"Eyre","sequence":"additional","affiliation":[{"name":"Haematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust Oxford United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Fehr","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology Cantonal Hospital St Gallen St. Gallen Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Gin\u00e9","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Cl\u00ednic of Barcelona Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), CIBERONC Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gomes da Silva","sequence":"additional","affiliation":[{"name":"Department of Hematology Portuguese Institute of Oncology Lisbon Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Klener","sequence":"additional","affiliation":[{"name":"First Dept. Of Internal Medicine\u2010Hematology University General Hospital Prague and First Faculty of Medicine, Charles University Prague Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ladetto","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine Division of Hematology, University of Eastern Piedmont Alessandria Italy"},{"name":"SCDU Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo Alessandria Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Ribrag","sequence":"additional","affiliation":[{"name":"Institut de Canc\u00e9rologie Gustave Roussy Villejuif France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Shpilberg","sequence":"additional","affiliation":[{"name":"Hematology Department Assuta Medical Center Tel\u2010Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Walewski","sequence":"additional","affiliation":[{"name":"Department of Lymphoid Malignancies Maria Sklodowska\u2010Curie National Research Institute of Oncology Warsaw"},{"name":"Department of Lymphoid Malignancies European Reference Network\/EuroBloodNet Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"Department of Medicine III LMU University Hospital Munich"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the EHA Guidelines Committee and the European MCL Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"National Cancer Institute Surveillance Epidemiology and End Results (SEER) Program. Accessed 15 Feb 2025.https:\/\/seer.cancer.gov\/seertools\/hemelymph\/51f6cf57e3e27c3994bd5357\/"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2011.09.010"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2508"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282632"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000928"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-559930"},{"key":"e_1_2_12_8_1","article-title":"Therapeutic advances and gradual improvement in overall survival in mantle cell lymphoma over four decades","author":"Alzahrani M","journal-title":"Br J Haematol"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18597"},{"key":"e_1_2_12_10_1","volume-title":"Haematolymphoid Tumours","year":"2024"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015851"},{"key":"e_1_2_12_12_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2017"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-862151"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.72"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.8387"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01977-y"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12308-009-0036-x"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-189505"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005289"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17023"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-628792"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-779736"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.214056"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-023-03676-6"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-797019"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02375-8"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011763"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022351"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000505"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01146-z"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.01.018"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16244189"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-230250"},{"issue":"2","key":"e_1_2_12_35_1","article-title":"Lack of benefit of autologous hematopoietic cell transplantation (auto\u2010HCT) in mantle cell lymphoma (MCL) patients (pts) in first complete remission (CR) with undetectable minimal residual disease (uMRD): initial report from the ECOG\u2010ACRIN EA4151 phase 3 randomized trial","volume":"144","author":"Fenske TS","year":"2024","journal-title":"Blood"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt139"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000302"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18697"},{"key":"e_1_2_12_40_1","unstructured":"MantS NaylorGU CrosbieN et al. A prospective analysis of newly diagnosed mantle cell lymphoma: predictors and survival of indolent disease. presented at: EHA24; 2024; Frankfurt."},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01797"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02321"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-192939"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199710"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70080"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg414"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx333"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx334"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.02.011"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00195-2"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14241"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30358-6"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01780"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01586"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00184-3"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx223"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02698"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023009744"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-201441"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01198-2"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024023944"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01294"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.7503"},{"key":"e_1_2_12_65_1","unstructured":"WangM MayerJ BeladaD et al. Acalabrutinib plus bendamustine and rituximab in untreated mantle cell lymphoma: results from the phase 3 double\u2010blind placebo\u2010controlled echo trial. presented at: EHA24; 2024; Frankfurt."},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201817"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30685-5"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02254-2"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-188788"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019030858"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200735"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025563"},{"key":"e_1_2_12_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008727"},{"key":"e_1_2_12_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179169"},{"issue":"1","key":"e_1_2_12_75_1","first-page":"343","article-title":"Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed\/refractory mantle cell lymphoma, including those with poor prognostic factors","volume":"109","author":"Le Gouill S","year":"2024","journal-title":"Haematologica"},{"key":"e_1_2_12_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33108-2"},{"key":"e_1_2_12_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635326"},{"key":"e_1_2_12_78_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_2_12_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009168"},{"key":"e_1_2_12_80_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3703"},{"key":"e_1_2_12_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014162"},{"key":"e_1_2_12_82_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00562"},{"key":"e_1_2_12_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102221"},{"key":"e_1_2_12_84_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715519"},{"key":"e_1_2_12_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00682-X"},{"key":"e_1_2_12_86_1","doi-asserted-by":"crossref","unstructured":"TamCS LasicaM SoumeraiJD et al. Combination treatment with novel BCL2 inhibitor sonrotoclax (BGB\u201011417) and zanubrutinib induces high rate of complete remission (CR) in patients with relapsed\/refractory mantle cell lymphoma (MCL). presented at: EHA 2025; 2025; Milan Italy.","DOI":"10.1002\/hon.70093_49"},{"key":"e_1_2_12_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30018-8"},{"key":"e_1_2_12_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011920"},{"key":"e_1_2_12_89_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-886457"},{"key":"e_1_2_12_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01013-3"},{"key":"e_1_2_12_91_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023525"},{"key":"e_1_2_12_92_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000712"},{"key":"e_1_2_12_93_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015560"},{"key":"e_1_2_12_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17363"},{"key":"e_1_2_12_95_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16922"},{"key":"e_1_2_12_96_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210"},{"key":"e_1_2_12_97_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00510"},{"key":"e_1_2_12_98_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006844"},{"key":"e_1_2_12_99_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.272500"},{"key":"e_1_2_12_100_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14870"},{"key":"e_1_2_12_101_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023009804"},{"key":"e_1_2_12_102_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19131"},{"key":"e_1_2_12_103_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023388"},{"key":"e_1_2_12_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00438-6"},{"issue":"5","key":"e_1_2_12_105_1","first-page":"1490","article-title":"Dose\u2010finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma","volume":"6","author":"Portell CA","year":"2022","journal-title":"Blood Adv"},{"key":"e_1_2_12_106_1","doi-asserted-by":"crossref","unstructured":"JurczakW WangM TrnenyM et al. Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the sympatico study. presented at: EHA24; 2024; Frankfurt.","DOI":"10.1016\/S2152-2650(24)01592-1"},{"key":"e_1_2_12_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70200-0"},{"key":"e_1_2_12_108_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18519"},{"key":"e_1_2_12_109_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16416"},{"key":"e_1_2_12_110_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008916"},{"key":"e_1_2_12_111_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0537-5"},{"key":"e_1_2_12_112_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"e_1_2_12_113_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02370"},{"key":"e_1_2_12_114_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02214"},{"key":"e_1_2_12_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00224-5"},{"key":"e_1_2_12_116_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0670"},{"key":"e_1_2_12_117_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02470"},{"key":"e_1_2_12_118_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-173946"},{"key":"e_1_2_12_119_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174956"},{"key":"e_1_2_12_120_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179872"},{"key":"e_1_2_12_121_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180109"},{"key":"e_1_2_12_122_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100001"},{"key":"e_1_2_12_123_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.2454"},{"key":"e_1_2_12_124_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-017-0067-3"},{"key":"e_1_2_12_125_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds054"},{"key":"e_1_2_12_126_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15721"},{"key":"e_1_2_12_127_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2241095"},{"key":"e_1_2_12_128_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-24-0178"},{"key":"e_1_2_12_129_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112673"},{"key":"e_1_2_12_130_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2024000534"},{"key":"e_1_2_12_131_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2024000535"},{"key":"e_1_2_12_132_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03084-6"},{"key":"e_1_2_12_133_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0057"}],"container-title":["HemaSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hem3.70233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:16:11Z","timestamp":1761826571000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hem3.70233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":132,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/hem3.70233"],"URL":"https:\/\/doi.org\/10.1002\/hem3.70233","archive":["Portico"],"relation":{},"ISSN":["2572-9241","2572-9241"],"issn-type":[{"value":"2572-9241","type":"print"},{"value":"2572-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2025-06-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70233"}}